This finding was not surprising, as upregulation of VEGF transcripts has also been described (Etcheverry et al. 2010), and anti-angiogenetic therapy (i.e., bevacizumab) has been used to prolong progression-free survival and to reduce clinical symptom burden in GBM (Ameratunga et al. 2018; Roth et al. 2020). The gene discussed is VEGFA; the disease is glioblastoma.